Press Release 2018-01-31

Press Release 2018-01-31

For Immediate Release: January 31, 2018

First Triojection cases in Germany were recently completed by Prof. Dr. Thomas Vogl MD.

Minimus Spine Inc., manufacturer of the patented Triojection System, intended to produce ozone gas for spinal disc herniations, announced today that the first cases of Triojection in Germany were recently performed. The cases were done at the University of Frankfurt and performed by Prof. Dr. Thomas Vogl MD, Director of the Institute for Diagnostic and Interventional Radiology at the J.W. Goethe University Hospital Frankfurt am Main.

“I successfully completed 10 Triojection cases in December”, said Dr.Vogl. “It is an elegant design and simple to use. I particularly appreciate how Triojection is designed for safety and consistency. Triojection is unique in that it creates the ozone inside a sterile syringe and simultaneously measures the concentration of ozone within the syringe. This product advances the state of the art and gives me a new level of confidence in what is actually administered to the patient’s disc. Early results have been favorable and I intend to continue with Triojection in my practice.”

David Hooper Ph.D., Minimus Spine’s CEO, added “We are excited to have Dr. Vogl as one of our earliest adopters. He is a leader in his field and his support validates our belief that Triojection sets a new standard for spinal ozone injections.”

Dr. Vogl is a listed author on more than 500 peer reviewed articles related to interventional radiology and currently sits on the editorial boards for the journals European Radiology and Academic Radiology. The University of Frankfurt has been performing spinal ozone injections for more than 10 years. In 2012, Dr. Vogl and his colleagues published a key paper describing the reduction of disk volume following intradiscal ozone injection in 283 subjects with disc herniation.

About Minimus Spine Inc.: Established in 2006, Minimus Spine is a privately held medical device company dedicated to developing the Triojection technology the non-surgical treatment of herniated discs. Minimus Spine’s CEO and team largely stem from Spinal Concepts, another spinal startup that was sold to Abbott for $170M. The company is positioning itself for sale to one of several medical device strategics after achieving successful European adoption of its product. Minimus Spine maintains its headquarters in Austin, TX. For more information on Minimus Spine, please visit or email